CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.

Stefania CrucittaMarzia Del ReFederico PaolieriFrancesco BloiseAndrea SbranaEnrico SammarcoChiara MercinelliFederico CucchiaraLorenzo FontanelliLuca GalliRomano Danesi

Published in: Cancer chemotherapy and pharmacology (2020)

These findings suggest an association between CYP17A1 c.-362T>C polymorphism and poorer clinical outcome with abiraterone for mCRPC patients. However, further validations on larger cohort of patients are needed to confirm its role as a predictive biomarker for abiraterone resistance.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
peritoneal dialysis
prognostic factors
squamous cell carcinoma